Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Target Raised at Robert W. Baird

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) had its price objective lifted by Robert W. Baird from $514.00 to $568.00 in a report released on Monday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird‘s target price suggests a potential upside of 73.10% from the company’s current price.

Other analysts have also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating on shares of Praxis Precision Medicines in a report on Wednesday. UBS Group began coverage on Praxis Precision Medicines in a report on Wednesday, October 14th. They set a “buy” rating and a $706.00 price objective for the company. Wall Street Zen cut shares of Praxis Precision Medicines from a “hold” rating to a “sell” rating in a research report on Saturday, October 17th. Royal Bank Of Canada upped their price objective on shares of Praxis Precision Medicines from $462.00 to $478.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 10th. Finally, Wedbush raised their target price on shares of Praxis Precision Medicines from $188.00 to $189.00 and gave the company an “underperform” rating in a research note on Tuesday, November 10th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $634.53.

View Our Latest Analysis on Praxis Precision Medicines

Praxis Precision Medicines Stock Performance

Shares of PRAX stock opened at $328.13 on Monday. The company has a market capitalization of $9.17 billion, a PE ratio of -25.64 and a beta of 2.85. Praxis Precision Medicines has a 52-week low of $160.11 and a 52-week high of $392.70. The business’s fifty day moving average is $289.90 and its 200 day moving average is $314.38.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last posted its earnings results on Monday, November 9th. The company reported ($3.23) EPS for the quarter, topping the consensus estimate of ($3.54) by $0.31. On average, sell-side analysts forecast that Praxis Precision Medicines will post -13.93 EPS for the current fiscal year.

Hedge Funds Weigh In On Praxis Precision Medicines

A number of hedge funds and other institutional investors have recently modified their holdings of PRAX. Seven Fleet Capital Management LP bought a new stake in Praxis Precision Medicines in the 2nd quarter worth approximately $2,524,000. Readystate Asset Management LP purchased a new stake in Praxis Precision Medicines in the second quarter worth approximately $3,531,000. Swiss National Bank boosted its stake in Praxis Precision Medicines by 15.3% in the first quarter. Swiss National Bank now owns 46,700 shares of the company’s stock worth $15,046,000 after buying an additional 6,200 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Praxis Precision Medicines in the second quarter worth approximately $2,698,000. Finally, Orbimed Advisors LLC boosted its stake in Praxis Precision Medicines by 82.5% in the first quarter. Orbimed Advisors LLC now owns 172,500 shares of the company’s stock worth $55,578,000 after buying an additional 78,000 shares in the last quarter. 67.84% of the stock is currently owned by hedge funds and other institutional investors.

Praxis Precision Medicines Company Profile

(Get Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.

Featured Articles

Analyst Recommendations for Praxis Precision Medicines (NASDAQ:PRAX)

Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.